| Antigen: |
CD9 |
| Relevance: |
CD9 antigen is a glycoprotein expressed on the surface of developing B lymphocytes, platelets, monocytes, eosinophils, basophil, stimulated T lymphocytes and neurons and glial cells in the peripheral nervous system. CD9 mediates platelet aggregation and activation via FcgRIIa. It may play a role in cell migration.
Antibodies against CD9 have utility in characterisation of acute leukaemias and in some cases AML and for functional studies on platelets |
| Clone: |
P1/33/2 |
| Subclass: |
IgG1 |
| Applications: |
Immunohistochemistry (Frozen sections), FACS |
| Immunogen: |
Acute lymphoblastic leukaemia cells |
| Reactivity: |
Human |
| Species raised in: |
Mouse |
| Fusion partner: |
NS-1 |
| Recommended growth conditions: |
RPMI 1640 + 10% FCS + penicillin (100U/ml) + streptomycin (100mg/l) + glutamine (2mM) + HAT |
| References: |
Jennings LK, Crossno JT, White MM (1993) CD9 cluster workshop report: cell surface binding and functional analysis. In Schlossman SF, et al (eds) Leucocyte Typing V, Vol 2, Oxford University Press, Oxford, New York and Tokyo, p 1249-51 |
| Notes: |
Please note this cell line has not been weaned out of HAT. Ultroser G can be used at 1% if the cells are not growing well |
For further information about antibodies from CRT or to discuss sales or licensing options, please contact us at reagents@cancertechnology.com
Click here to view Notes and Disclaimer information |
